The Engaging Upsides of ResMed
ResMed Inc. (RMD) has been sailing smoothly on the crest of its cloud-connected platforms, AirSense10 and AirSense11. The symbiosis of these innovative devices with the myAir app, particularly in tandem with AirSense 11, is steering patients towards better therapy adherence. Despite these golden promises, the specter of increasing debt levels and a competitive battleground lurk in the shadows.
The Market Success
The Zacks Rank #2 (Buy) member, ResMed Inc., has seen a meteoric rise of 36.7% in the past six months, clearly outshining the industry’s ascent of 16.1% and the S&P 500 composite’s 23% hike.
The Financial Landscape
At the helm of ResMed Inc. is a flagship boasting a market capitalization of $29.13 billion. Over the fiscal quarters, the company’s earnings have thrust past estimates thrice, while falling short in one instance. The earnings surprise average stands at a commendable 1.83%.
Ready for a deeper dive into the ResMed universe? Let’s press further.
Exploring the Bright Horizons
Recovery in Device Sales: A surge in device sales continues to steer ResMed’s revenue northward, courtesy of the consistent availability of AirSense 10 and AirSense 11 sleep devices. In the global theater of device sales, there was an 11% upsurge, with regions like the United States, Canada, and Latin America seeing a 7% rise. On the other hand, Europe, Asia, and other markets witnessed a remarkable 16% hike.
Increased Focus on International Markets: With eyes locked on growing markets such as China, South Korea, India, and Brazil, among others, ResMed is carving a niche. In the second fiscal quarter of 2024, sales surged by 12% in Europe, Asia, and other regions. A global uptick of 11% in device sales and a 9% spike in masks and other sales signal strong growth.
Potential in Digital Health: Digital health forms the cornerstone of ResMed’s grand plans. The edifice stands tall on global digital health technology initiatives aimed at enhancing the connected healthcare ecosystem. With acclaimed products like AirView and myAir, entirely cloud-based, ResMed’s trajectory knows no bounds.
Challenges on the Horizon
Escalating Debt Level: A looming challenge for ResMed is the towering debt level. By the end of 2023, long-term debt breached the $1.26 billion mark, a stark contrast to the meager $210.2 million in cash and cash equivalents. The high debt poses a risk with elevated interest payments, necessitating caution.
Competitive Landscape: The realm of SDB products pulsates with vibrancy but also throbs with cut-throat competition. Standing toe to toe with stalwarts like Philips BV, DeVilbiss Healthcare, and others requires ResMed to constantly sharpen its competitive edge in terms of pricing, features, and reliability.
Forecasting the Future
The Zacks Consensus Estimate for RMD’s fiscal 2024 EPS has ascended from $7.39 to $7.45 in the last 90 days. Additionally, the revenue forecast for fiscal 2024 pegs at a robust $4.65 billion, marking a 10.03% surge from the previous year.
Exploring Other Avenues
Looking beyond ResMed, other stars in the medical firmament include Stryker Corporation (SYK), Cencora, Inc. (COR), and Cardinal Health (CAH).
Stryker, a Zacks Rank #2 entity, soared with an estimated earnings growth rate of 11.5% for 2025, surpassing the S&P 500’s 9.9% mark. Cencora, holding a Zacks Rank #2 spot, boasts a stellar earnings yield of 5.75%. Equally competent is Cardinal Health, with a Zacks Rank #2 tag and a robust long-term estimated earnings growth rate of 15.3%.
Ready to dive into the world of prospects?
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
